Catalent to purchase Metrics Contract Services from Mayne Pharma
Metrics’ Greenville facility will be integrated into oral development and manufacturing network of Catalent.

Metrics’ Greenville facility will be integrated into oral development and manufacturing network of Catalent.
GBT takeover complements and boosts Pfizer’s expertise in rare haematology.
The darolutamide combination treatment substantially lowered mortality risk by 32.5% in mHSPC patients.
The approval was based on findings from the Phase III DESTINY-Breast04 trial of Enhertu.
The companies will co-market the drug in the region and will be made available soon.
The approval was based on the Phase III OlympiA clinical trial of Lynparza versus placebo.
The board of directors of Amgen and ChemoCentryx has granted unanimous approval for the acquisition.
Gilead will gain access to the discovery platform and complete line of the immune inhibitory receptor agonists of MiroBio.
Four vaccines for infectious diseases are currently in the Phase III development stage.
Thank you for subscribing to Pharmaceutical Technology